Functional Concept
GSK Secures Another Legal Victory in Latest Zantac Verdict
GSK, Zantac, legal victory, cancer claims, ranitidine, NDMA, FDA, pharmaceutical litigation
Symbiotic Capital Launches with $600M, Ties to Arie Belldegrun’s Bellco
Symbiotic Capital, Arie Belldegrun, Bellco, $600M, credit firm, biotech, private equity
Agios’ Pyrukynd Misses Primary Endpoint in First Pediatric Study for Rare Blood Disorder
Agios Pharmaceuticals, Pyrukynd, mitapivat, PK deficiency, pediatric study, blood disorder, Phase 3 ACTIVATE-KidsT study
Sanofi Invests €1.3 Billion in Next-Generation Insulin Facility in Frankfurt
Sanofi, insulin facility, Frankfurt, diabetes treatment, next-generation insulin, €1.3 billion investment
Valneva Invests $10M in LimmaTech for Clinical-Stage Shigella Vaccine
Valneva, LimmaTech, Shigella vaccine, clinical-stage, biotech, pharmaceuticals, vaccine development
IDEAYA Secures $400M Option Deal with Biocytogen for Bispecific ADC
IDEAYA Biosciences, Biocytogen, Bispecific ADC, Option Deal, Cancer Treatment
FibroGen Lays Off 75% of US Staff After Cancer Drug Fails in Two Phase III Trials
FibroGen, cancer drug, layoffs, Phase III trials, pamrevlumab, oncology, pancreatic cancer, chemotherapy, anaemia therapy, roxadustat, Astellas, AstraZeneca
GSK Abandons Phase 2 HPV Vaccine Due to Lack of Best-in-Class Potential
GSK, HPV vaccine, phase 2, best-in-class potential, vaccine development
Celldexs anti-cKIT antibody proves it can reduce chronic hives in another phase 2 trial
Antibodies, Trial Phase, Urticaria, chronic hives
Ventyx Abandons TYK2 Inhibitor Development Following Phase II Failure in Crohn’s Disease
Ventyx Biosciences, TYK2 inhibitor, VTX958, Crohn’s disease, Phase II trial, drug development failure